Technology Transfer

The Bayh-Dole Act (35 U.S.C. §§ 200–212), enacted in 1980, is the federal law that transformed U.S. technology commercialization by allowing universities, small businesses, and non-profit organizations that receive federal research funding to elect to retain title to inventions made with that funding. Before Bayh-Dole, the U.S. government automatically owned inventions arising from federally funded research — resulting in thousands of unpatented or unlicensed federally funded inventions that never reached the market. A 1978 study found that of approximately 28,000 patents held by the U.S. government, fewer than 5% were licensed to industry. By allowing institutions to own the patents themselves and license them to private companies with the profit motive to commercialize, Bayh-Dole created the incentive structure that makes university technology transfer economically viable. Key provisions: (1) Universities may elect to retain title to federally funded inventions and must disclose inventions to the funding agency. (2) The federal government retains a paid-up non-exclusive license for government use — but not commercial exploitation. (3) Universities must share licensing revenue with inventors. (4) Products sold in the U.S. must be 'substantially manufactured in the United States' (waivable). (5) The funding agency retains 'march-in rights' to require licensing if the university fails to commercialize — these have never been exercised as of 2026. (6) Universities must file patent applications and diligently attempt to commercialize. Impact: U.S. universities now receive approximately $3–4 billion per year in licensing revenue (AUTM data), have formed thousands of spinout companies, and the Bayh-Dole framework has been copied by dozens of countries.

A technology transfer office (TTO) — also called an office of technology commercialization (OTC), office of technology licensing (OTL), or technology licensing office (TLO) — is the university or research institution department responsible for commercializing intellectual property arising from research. Core functions: (1) Receiving and evaluating invention disclosures — TTOs review disclosures for patentability, commercial potential, and competitive landscape before deciding whether to file a patent application. Universities disclose thousands of inventions annually but patent only a fraction. (2) Filing and prosecuting patent applications — TTOs engage outside patent counsel and manage the prosecution process. Prosecution costs are typically advanced by the institution and recovered from licensing revenue. (3) Marketing technologies to industry — TTOs reach out to companies that may be interested in licensing, maintain databases of available technologies on their websites, and attend industry conferences. (4) Negotiating and executing license agreements — terms include royalty rates, exclusivity scope, field-of-use restrictions, milestone payments, diligence obligations, sublicensing terms, and government-rights compliance. (5) Supporting spinout formation — when no existing company wants to license, TTOs support formation of startup companies (spinouts) by current or former university employees or graduate students. Equity stakes of 5–15% to the university are common. (6) Compliance with Bayh-Dole — TTOs ensure federally funded inventions are reported to agencies within required timeframes and that licensing agreements include required government rights provisions. Scale: MIT's Technology Licensing Office licenses approximately 100–150 inventions per year and derives about $100M+ annually in licensing revenue; Stanford OTL has licensed thousands of inventions since its founding in 1970 and derived significant revenue from Google's founding IP (PageRank). Most university TTOs, however, are smaller — AUTM data shows a median of 15–20 license agreements per institution per year.

An exclusive license gives one licensee the right to practice the technology within a defined field of use and/or territory, excluding even the university from licensing the same rights to other parties. A non-exclusive license allows the university to grant the same rights to multiple parties — theoretically unlimited licensees. Exclusive licenses: (1) Higher value to the licensee — the licensee can invest in product development without fear that a competitor will get the same technology. This justifies higher upfront fees, higher royalties, and commercial commitments. (2) Require diligence obligations — because an exclusive license has market-exclusion effects, TTOs impose development milestones (e.g., 'file IND within 3 years,' 'achieve commercial sale within 5 years,' 'minimum annual royalties') to prevent a company from taking a patent off the market and shelving it. (3) Narrower field-of-use — licenses can be exclusive within one therapeutic area but non-exclusive in others, allowing multiple exclusive licensees in different markets from the same patent. (4) Sublicensing — exclusive licensees typically have sublicensing rights (with revenue sharing back to the university) but may need university consent for sublicenses. Non-exclusive licenses: (1) Better for widely-used technologies — research tool patents (promoter sequences, model organisms, assay techniques) are often licensed non-exclusively so many researchers can use them. (2) Lower royalties and simpler terms — typically lower rates ($500–$5,000/year or running royalties of 1–3%) with minimal diligence since market competition drives commercialization. (3) No shelter from competition — the licensee cannot prevent the university from licensing to competitors. Field-of-use limitations: most university licenses are exclusive within a defined field of use — e.g., exclusive for human therapeutic applications but non-exclusive for research use and animal health. This allows maximum commercial development of each field while avoiding a single company holding all rights.

As of 2026, march-in rights have NEVER been exercised by any federal agency under Bayh-Dole. March-in rights are the ability of the funding federal agency to require the patent holder (typically a university or its licensee) to grant licenses to third parties — or to practice the invention itself — under 35 U.S.C. § 203. Grounds for march-in: (a) the contractor has not taken or is not expected to take effective steps to achieve practical application of the invention; (b) action is necessary to alleviate health or safety needs not being reasonably satisfied; (c) action is necessary to meet requirements of federal regulations (e.g., DEA, FDA); (d) the contractor has not complied with domestic manufacturing preferences. Most notable petitions denied: In 2004, consumer advocates petitioned NIH to march in on Abbott Laboratories' HIV drug ritonavir (Norvir), arguing the price increase from $1.71 to $8.57 per pill required action. NIH denied the petition, stating that Bayh-Dole 'was not intended to be used as a price control mechanism.' Similar petitions for other HIV medications, Fabrazyme, and other drugs have all been denied on similar grounds. Key policy debate: Proponents of exercising march-in rights argue that taxpayers fund the research and high drug prices are an appropriate trigger; opponents argue that Bayh-Dole was designed to encourage commercialization (which requires investor returns), and using march-in as a price-control tool would chill investment in federally funded technologies by making future commercialization returns uncertain. In 2024, the Biden administration issued proposed guidelines that would, for the first time, consider price as a factor in march-in analysis — but this guidance remained contested and had not been applied as of 2026.

A university spinout (or spin-off, spinoff, startup) is a company formed to commercialize a technology licensed from a university or research institution, typically when no established company is willing to license the technology. Formation process: (1) Inventors (usually faculty, postdocs, or graduate students) identify commercial potential and approach the TTO. (2) TTO evaluates the invention and may help structure the company — some TTOs have dedicated entrepreneurship programs, incubators, and seed funding connections. (3) The spinout company is formed (usually a Delaware C-Corp for venture investment) and executes a license agreement with the university. The license is typically exclusive in the spinout's target field of use, with royalties, milestones, and equity to the university. (4) Founders bring in co-founders, advisors, and seek seed/angel or venture funding. (5) The company commercializes the technology — which often means years of additional development, regulatory work, and fundraising before a product is on the market. Equity to the university: TTOs typically receive 5–15% equity at founding, sometimes with anti-dilution rights. Many TTO equity stakes are small enough that VC investors don't object. Some TTOs (Stanford, MIT, Caltech) have generated hundreds of millions of dollars from successful spinout equity stakes. Faculty conflicts of interest: most universities restrict faculty from running a spinout full-time while employed — common structures require sabbatical, part-time appointment, or a clear separation of academic and company work. Companies cannot direct research performed with university resources. AUTM data: U.S. universities created approximately 1,000+ new spinout companies per year as of recent AUTM surveys. Successful spinouts from university IP include: Google (Stanford — PageRank), Genentech (UCSF), Qualcomm (UCSD), Dolby (MIT), and hundreds of pharmaceutical companies built on NIH-funded research.